Current status of DILD in molecular targeted therapies

International Journal of Clinical Oncology

Volumn 17, Issue 6, 2012, Pages 534-541

  Saito, Yoshinobu ^a   Gemma, Akihiko ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Drug induced interstitial lung disease; Epidemiology; Management; Molecular targeted drug

Indexed keywords

BEVACIZUMAB; BORTEZOMIB; CALICHEAMICIN; CETUXIMAB; CORTICOSTEROID; CYCLOSPORIN; DASATINIB; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IMATINIB; IRINOTECAN; LAPATINIB; NILOTINIB; OXALIPLATIN; PANITUMUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LUNG INJURY; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT RESPIRATORY DISTRESS SYNDROME; BACTERIUM CULTURE; BLOOD EXAMINATION; BREAST CANCER; BRONCHOSCOPY; CANCER COMBINATION CHEMOTHERAPY; CAPILLARY LEAK SYNDROME; CARDIAC GRAFT REJECTION; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EARLY DIAGNOSIS; EOSINOPHILIC LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; HYPEREOSINOPHILIC SYNDROME; HYPOXEMIA; INCIDENCE; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; JAPAN; KIDNEY CARCINOMA; KIDNEY GRAFT REJECTION; LIVER CELL CARCINOMA; LUNG BIOPSY; LUNG INJURY; LUNG NON SMALL CELL CANCER; LUNG VOLUME; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; MULTIPLE MYELOMA; NONCARDIOGENIC LUNG EDEMA; OUTCOME ASSESSMENT; OXYGEN DESATURATION; PANCREAS CANCER; PANCREATIC NEUROENDOCRINE TUMOR; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; SMOKING; THORAX RADIOGRAPHY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LUNG DISEASES, INTERSTITIAL; MOLECULAR TARGETED THERAPY; RISK FACTORS;

EID: 84880699591     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0494-5     Document Type: Review

References (31)

1. Inoue A, Saijo Y, Maemondo M et al (2003) Severe acute interstitial pneumonia and gefitinib. Lancet 361:137-139
2. Pharmaceuticals and Medical Devices Agency (2004), Reports on Iressa Tablets 250 prospective study (special investigation). In: Pharmaceuticals and Medical Devices Safety Information. No. 206 October 2004. http://www.pmda.go.jp/ english/service/pdf/precautions/PMDSI-206.pdf. Accessed Oct 2012
3. Kudoh S, Kato H, Nishiwaki Y et al (2008) Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study. Am J Respir Crit Care Med 177:1348-1357
4. Kubota K, Nishiwaki Y, Tamura T et al (2008) Efficacy and safety of erlotinib monotherapy for Japanese patients with advanced non-small cell lung cancer: a phase II study. J Thorac Oncol 3:1439-1445
5. Nakagawa K, Kudoh S, Ohe Y et al (2012) Postmarketing surveillance study of erlotinib in Japanese patients with non-small-cell lung cancer (NSCLC): an interim analysis of 3488 patients (POLARSTAR). J Thorac Oncol 7:1296-1303
6. Okamoto I, Fujii K, Matsumoto M et al (2003) Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer. Lung Cancer 40:339-342
7. Camus P, Kudoh S, Ebina M (2004) Interstitial lung disease associated with drug therapy. Br J Cancer 91(suppl 2):S18-S23
8. Makris D, Scherpereel A, Copin MC et al (2007) Fatal interstitial lung disease associated with oral erlotinib therapy for lung cancer. BMC Cancer 7:150
9. Lind JS, Smit EF, Grünberg K et al (2008) Fatal interstitial lung disease after erlotinib for non-small cell lung cancer. J Thorac Oncol 3:1050-1053
10. Okusaka T, Furuse J, Funakoshi A et al (2011) Phase II study of erlotinib plus gemcitabine in Japanese patients with unresectable pancreatic cancer. Cancer Sci 102:425-431
11. Ishiguro M, Watanabe T, Yamaguchi K et al (2012) A Japanese post-marketing surveillance of cetuximab (Erbitux®) in patients with metastatic colorectal cancer. Jpn J Clin Oncol 42:287-294
12. Takeda Pharmaceutical Company Limited (2012) http://www.vectibix-takeda. com/files/chousa.pdf (in Japanese). Accessed Oct 2012
13. Chugai Pharmaceutical Co., Ltd. (2012) http://chugai-pharm.jp/hc/ss/pr/ safe/report/ava/index.html (in Japanese). Accessed Oct 2012
14. Miyakoshi S, Kami M, Yuji K et al (2006) Severe pulmonary complications in Japanese patients after bortezomib treatment for refractory multiple myeloma. Blood 107:3492-3494
15. Gotoh A, Ohyashiki K, Oshimi K et al (2006) Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "lung injury by bortezomib" joint committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology. Int J Hematol 84:406-412
16. Mukai H, Ohyashiki K, Katoh T et al (2011) Lung injury associated with bortezomib therapy in Japan. Rinsho Ketsueki 52:1859-1869 (in Japanese)
17. Horiuchi-Yamamoto Y, Gemma A, Taniguchi H et al (2012) Drug-induced lung injury associated with sorafenib: analysis of all-patient post-marketing surveillance in Japan. Int J Clin Oncol. doi: 10.1007/s10147-012-0438-0 (Epub ahead of print)
18. Pfizer Japan Inc. (2012) http://pfizerpro.jp/cs/sv/sutent/pms/report.html (in Japanese). Accessed Oct 2012
19. Bristol-Myers K.K. (2012) http://www.sprycel.jp/pdf/investigation/ tyukankaiseki-20101006.pdf (in Japanese). Accessed Oct 2012
20. Novartis Pharma K.K. (2012) http://product.novartis.co.jp/tas/ts/pms- chukan-1.pdf (in Japanese). Accessed Oct 2012
21. Ohnishi K, Sakai F, Kudoh S et al (2006) Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 20:1162-1164
22. Pfizer Japan Inc. (2012) https://pfizerpro.jp/download.php?key= 4yTxchfb450= (in Japanese). Accessed Oct 2012
23. Glaxo Smith Kline K.K. http://tykerb.jp/pdf/chosagaiyo.pdf (in Japanese). Accessed Oct 2012
24. White DA, Camus P, Endo M et al (2010) Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. Am J Respir Crit Care Med 182:396-403
25. Yao JC, Shah MH, Ito T et al (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364:514-523
26. Bellmunt J, Szczylik C, Feingold J et al (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19:1387-1392
27. Maroto JP, Hudes G, Dutcher JP et al (2011) Drug-related pneumonitis in patients with advanced renal cell carcinoma treated with temsirolimus. J Clin Oncol 29:1750-1756
28. Camus P (2003) Drug induced infiltrative lung diseases. In: Schwarz MI, King TE (eds) Interstitial lung disease, 4th edn. Decker, London, pp 485-534
29. Müller NL, White DA, Jiang H et al (2004) Diagnosis and management of drug-associated interstitial lung disease. Br J Cancer Suppl 2:S24-S30
30. Novartis Pharma K.K. (2012) http://product.novartis.co.jp/afi/tg/te-afi- RCC-201209.pdf (in Japanese). Accessed Oct 2012
31. Pfizer Japan Inc. (2012) http://pfizerpro.jp/documents/info/tor01info.pdf (in Japanese). Accessed Oct 2012